# Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

> **NCT05842954** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1720 (actual)

## Conditions studied

- Uncomplicated Plasmodium Falciparum Malaria

## Interventions

- **DRUG:** KLU156
- **DRUG:** Coartem

## Key facts

- **NCT ID:** NCT05842954
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-07
- **Primary completion:** 2025-06-27
- **Final completion:** 2025-11-25
- **Target enrollment:** 1720 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842954, "Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05842954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*